Johnson & Johnson Innovation - JJDC

TECLens, LLC is a development stage company based in St. James, New York, focused on designing and manufacturing medical contact lenses for myopia treatment. Established in 2013, the company has developed a non-invasive therapy involving the use of its product, the CXLens (Corneal Crosslinking Lens), which is worn for just half an hour in a doctor's office. This innovative lens features real-time ultrasound sensing and a high oxygen concentration environment to ensure precise targeting and stability during treatment. TECLens aims to address various vision issues, including progressive myopia in children and vision problems in adults, such as hyperopia and low-order myopia. Its technology is designed to improve patients' eye health and potentially reduce the long-term risks associated with traditional corrective lenses.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Solenic Medical, a medical device company that develops a non-invasive treatment for infected metallic implants in the body. The company leverages the properties of alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries, such as knee and hip replacements, as well as in trauma-related implants such as plates and rods. Its AMF technology has the potential to completely replace the very expensive and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Rajiv Chopra and David Greenberg founded it in College Station, Texas in 2019.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

DocSpera is an integrated surgical coordination platform that enhances workflow efficiencies and patient care by streamlining synchronization across various sites and teams. Its proprietary technology automates pre-surgical coordination and facilitates real-time, secure case and image synchronization among surgeons, care teams, and device suppliers, utilizing electronic health record (EHR) data. The platform also provides real-time patient insights and operating room dashboards, enabling continuous monitoring of patients from the surgical decision point through recovery. Headquartered in Sunnyvale, California, DocSpera operates under Compliant Innovations Inc.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

FlexDex Inc. is a company focused on developing minimally invasive surgery (MIS) devices. Its innovative platform technology allows for the translation of a surgeon's hand, wrist, and arm movements from outside the patient into precise movements of an end-effector inside the body, thereby enhancing the functionality of MIS instruments and endoscopes. The company collaborates with distributors to serve healthcare professionals both in the United States and internationally. Founded in 2010 and based in Brighton, Michigan, FlexDex aims to improve surgical outcomes through its advanced medical device technology.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that operates web-based platforms tailored to patients with chronic conditions. Founded in 2016, the company offers a range of specialized healthcare brands, including Keeps for men’s hair loss, Cove for migraines, Picnic for allergies, Facet for skin conditions, and NURX for sexual health. Each brand is designed to provide personalized treatments and care, addressing the unique needs of its community. By focusing on specific ongoing conditions, Thirty Madison seeks to empower individuals through accessible and effective healthcare solutions, facilitating exceptional outcomes for patients over a lifetime of care.

Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that operates web-based platforms tailored to patients with chronic conditions. Founded in 2016, the company offers a range of specialized healthcare brands, including Keeps for men’s hair loss, Cove for migraines, Picnic for allergies, Facet for skin conditions, and NURX for sexual health. Each brand is designed to provide personalized treatments and care, addressing the unique needs of its community. By focusing on specific ongoing conditions, Thirty Madison seeks to empower individuals through accessible and effective healthcare solutions, facilitating exceptional outcomes for patients over a lifetime of care.

Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

OrthoSpin is developing innovative robotic external fixation system that will improve patient treatment and allow a real-time review to reduce complications and improve clinical outcomes. Dynamic external fixators are mainly used for trauma, bone lengthening and congenital deformities correction. Those systems are cumbersome, painful and require high maintenance. With OrthoSpin’s smart system, physicians are assured that the prescribed course of treatment is being followed. The Company’s proprietary software program allows physicians to chart patient progress and, if required, to easily change the treatment schedule.

TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

OrthoSpin is developing innovative robotic external fixation system that will improve patient treatment and allow a real-time review to reduce complications and improve clinical outcomes. Dynamic external fixators are mainly used for trauma, bone lengthening and congenital deformities correction. Those systems are cumbersome, painful and require high maintenance. With OrthoSpin’s smart system, physicians are assured that the prescribed course of treatment is being followed. The Company’s proprietary software program allows physicians to chart patient progress and, if required, to easily change the treatment schedule.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.